On July 1, 2025, Beam Therapeutics Inc. acquired an early-stage life sciences company by issuing 403,128 shares of common stock upfront and potentially up to $89 million in additional milestone payments depending on future achievements, which may also be in stock. This acquisition involves a maximum potential of 5,232,216 shares tied to these milestones, reflecting a significant investment strategy.